Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 21,139 | 17,192 | 18,092 | 16,097 | 16,604 |
| Cost of Goods | 2,443 | 2,265 | 2,263 | 2,020 | 1,846 |
| Gross Profit | 18,696 | 14,927 | 15,829 | 14,077 | 14,758 |
| Operating Expenses | 34,521 | 37,237 | 36,374 | 32,184 | 34,319 |
| Operating Income | -15,382 | -22,045 | -20,282 | -18,087 | -18,715 |
| Interest Expense | 3,761 | 3,553 | 3,223 | 2,694 | 2,239 |
| Other Income | -4,939 | -4,594 | -4,675 | -4,341 | -5,705 |
| Pre-tax Income | -24,082 | -30,192 | -28,180 | -25,122 | -26,659 |
| Income Tax | 54 | 21 | 689 | 709 | 32 |
| Net Income Continuous | -24,136 | -30,213 | -28,869 | -25,831 | -26,691 |
| Net Income | $-24,136 | $-30,213 | $-28,869 | $-25,831 | $-26,691 |
| EPS Basic Total Ops | -1.03 | -1.30 | -1.25 | -1.13 | -1.18 |
| EPS Basic Continuous Ops | -1.03 | -1.30 | -1.25 | -1.13 | -1.18 |
| EPS Diluted Total Ops | -1.03 | -1.30 | -1.25 | -1.13 | -1.18 |
| EPS Diluted Continuous Ops | -1.03 | -1.30 | -1.25 | -1.13 | -1.18 |
| EBITDA(a) | $-15,483 | $-22,182 | $-20,451 | $-18,110 | $-18,362 |